Zoom Logo

(Ref 151600) Diagnostics Crisis - convened by Lancet Commission on Diagnostics - Shared screen with speaker view
Ed Rybicki
34:41
South Africa was able to do emergency diagnostics development for SARS2 - everything from antigens and antibodies made in plants, to positive control RNA targets for PCR amplification. Also made in plants B-)
Ed Rybicki
36:13
Need presentation view for Mlisana slides?
Ed Rybicki
36:25
👍
Kenneth Fleming
53:20
I suggest the lesson from South Africa is that we can improve things. It takes the policy makers to priorities and allocate resources!
Ed Rybicki
54:09
It is VERY obvious that, together with drastic improvement in Africa’s vaccine manufacturing capacity, should come a parallel improvement in capacity to make the reagents to go into diagnostic kits for use in Africa for neglected diseases in Africa.
Kenneth Fleming
54:22
agree
Ed Rybicki
54:38
👍
Koleka Mlisana
56:40
Fully agree - prioritisation must come with resources for sustainability
Ed Rybicki
57:03
Great story about NHLS, Koleka!
Koleka Mlisana
58:41
🙏 thanks
Ed Rybicki
59:15
A One Health approach is to be recommended: make reagents that can be used as diagnostics, and potentially as vaccines - for animals and/or people.
Ed Rybicki
01:02:18
Thanks Marleen!
BELINDA SHAW
01:04:41
Our plant-based system produced a full suite of Covid-reagents for Diagnostics very quickly but unfortunately local rapid diagnostic kit manufacturers had to wait a long time to get regulatory approval for their antigen kits, resulting in them not being able to get into the market timeously and the market being flooded by imports which in themselves do not add any value to the industry by the way of employment, skills development and support of local manufacturers.
Ed Rybicki
01:04:53
Are there concrete plans to actually fund initiatives in Africa to make reagents for use as diagnostics, past the end of the COVID pandemic?
Kenneth Fleming
01:06:48
This is the opportunity and we must seize it. It is in our hands. We should recruit a small number of Africa countries who are interested and make specific proposals to EU. There are many possibilities.
Ed Rybicki
01:10:12
Possibilities: I like possibilities B-) Eh, Belinda??
Marleen Temmerman
01:10:50
thanks for great session Declan and colleagues. Sorry that I have to leave already, flight to catch :)
BELINDA SHAW
01:11:48
Home testing for Covid is common internationally. Is SAHPRA considering allowing home based testing?
BELINDA SHAW
01:12:41
Yes!
BELINDA SHAW
01:14:26
Thanks Ed!
Ed Rybicki
01:14:42
And??
Ed Rybicki
01:16:45
Declan, Kenneth, we need Manhattan Project-Type initiatives - and NOT competitive project-driven individual applications - to develop in this area. Otherwise it’s all piecemeal.
Kenneth Fleming
01:17:20
Agree!! We should set up a process to take this forward
Ed Rybicki
01:17:33
Maybe working with FIND?
Declan KIRRANE
01:18:16
Absolutley
Ed Rybicki
01:20:38
Thanks, Marta!
Ed Rybicki
01:22:17
Tying in with the AU PAVM Initiative could be useful - given recent plans of action already exist?
Koleka Mlisana
01:22:23
Thanks Marta - agree FIND becomes a possible vehicle to drive some of these efforts.
Marta Fernandez Suarez, FIND
01:25:38
Thanks, Koleka. We want to make the alliance concept a reality, because it will take all of us. We are all in agreement that need to use the current momentum to jointly step up the lobbying. As Kenneth just said, one voice is critical.
Koleka Mlisana
01:27:32
I unfortunately have to drop off for another meeting. Thank you for this great session and I look forward to participating in crafting a way forward.
Marta Fernandez Suarez, FIND
01:29:26
I concur with Kenneth on the imaging front, and while not a traditional focus on FIND, it is part of our new strategy to explore gaps and opportunities.
Ed Rybicki
01:30:43
Vaccines for the nastiest pathogens developing AMR….
Ralf Sudbrak
01:30:59
fully agree
Ed Rybicki
01:31:13
Great session: thanks, all!
BELINDA SHAW
01:31:15
Thanks Declan.